Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
162 hedge funds and large institutions have $1.47B invested in Acorda Therapeutics in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 63 increasing their positions, 45 reducing their positions, and 15 closing their positions.
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
40% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 45
7% more funds holding
Funds holding: 152 → 162 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $1.57B → $1.47B (-$95M)
38% less call options, than puts
Call options by funds: $2.85M | Put options by funds: $4.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$38.1M |
| 2 |
Millennium Management
New York
|
+$24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.4M |
| 5 |
Jennison Associates
New York
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$35.7M |
| 2 |
Goldman Sachs
New York
|
-$29.3M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$27.4M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$22.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$13.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Schroder Investment Management Group
London,
United Kingdom
| – | -$87.3K | -19 | Closed |
|
|
DVM
177
Dreman Value Management
West Palm Beach,
Florida
| – | -$58K | -13 | Closed |
|
|
TDC
178
Thompson Davis & Co
Richmond,
Virginia
| – | -$10K | -2 | Closed |
|
ACOR Hedge Fund Activity: Q2 2014 in Review
162 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2014, worth a combined $1.47B — down 6.1% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ACOR positions and 15 closed out — a net gain of 11 holders — while 63 added to existing stakes and 45 trimmed.
The largest buyer was Bridger Management, opening a new position worth an estimated $38.1M. The largest seller was Franklin Resources, exiting entirely with an estimated $35.7M sold.
- 162 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2014, up from 152 in Q1 2014.
- Funds reported $1.47B of Acorda Therapeutics stock for Q2 2014, down 6.1% quarter-over-quarter.
- 26 funds opened new Acorda Therapeutics positions in Q2 2014 and 15 closed out, a net change of +11 holders.
- The largest Acorda Therapeutics buyer in Q2 2014 was Bridger Management, an estimated $38.1M added.
- The largest Acorda Therapeutics seller in Q2 2014 was Franklin Resources, an estimated $35.7M sold.
Based on aggregated 13F filings for Q2 2014.